Keros Therapeutics, Inc. Quarterly Debt-to-equity in % from Q3 2020 to Q2 2024

Taxonomy & unit: ratio: %
Description: Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary: Keros Therapeutics, Inc. quarterly Debt-to-equity history and growth rate from Q3 2020 to Q2 2024.
Keros Therapeutics, Inc. Debt-to-equity for the quarter ending June 30, 2024 was 8.93 %, a 6.69% increase year-over-year.

Debt-to-equity, Quarterly (%)

Debt-to-equity, YoY Quarterly Growth (%)

Period	Value	YoY Chg	Change %	Date
Q2 2024	8.93	+0.56	+6.69%	Jun 30, 2024
Q1 2024	9.24	+1.33	+16.8%	Mar 31, 2024
Q4 2023	9.75	+2.62	+36.7%	Dec 31, 2023
Q3 2023	9.51	+3.99	+72.3%	Sep 30, 2023
Q2 2023	8.37	+2.72	+48.1%	Jun 30, 2023
Q1 2023	7.91	+3.24	+69.4%	Mar 31, 2023
Q4 2022	7.13	+2.83	+65.7%	Dec 31, 2022
Q3 2022	5.52	+1.75	+46.4%	Sep 30, 2022
Q2 2022	5.65	+1.96	+53.1%	Jun 30, 2022
Q1 2022	4.67	+0.37	+8.6%	Mar 31, 2022
Q4 2021	4.31	-2.38	-35.6%	Dec 31, 2021
Q3 2021	3.77	-12.4	-76.7%	Sep 30, 2021
Q2 2021	3.69			Jun 30, 2021
Q1 2021	4.3			Mar 31, 2021
Q4 2020	6.68			Dec 31, 2020
Q3 2020	16.1			Sep 30, 2020

* An asterisk sign (*) next to the value indicates that the value is likely invalid.